natgillin/translations-raw huggingface dataset:
1 ml injektionsvæske, opløsning (100 µg/ml darbepoetin alfa) i et hætteglas af type 1-glas med fluoropolymer-belagt elastomerprop og aluminiumsforsegling med flipoff-hætte.
1 ml solution for injection (100 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml injektionsvæske, opløsning (200 µg/ml darbepoetin alfa) i et hætteglas af type 1-glas med fluoropolymer-belagt elastomerprop og aluminiumsforsegling med flipoff-hætte.
1 ml solution for injection (200 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml injektionsvæske, opløsning (25 µg/ml darbepoetin alfa) i et hætteglas af type 1-glas med fluoropolymer-belagt elastomerprop og aluminiumsforsegling med flipoff-hætte.
1 ml solution for injection (25 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml injektionsvæske, opløsning (300 µg/ml darbepoetin alfa) i et hætteglas af type 1-glas med fluoropolymer-belagt elastomerprop og aluminiumsforsegling med flipoff-hætte.
1 ml solution for injection (300 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml injektionsvæske, opløsning (40 µg/ml darbepoetin alfa) i et hætteglas af type 1-glas med fluoropolymer-belagt elastomerprop og aluminiumsforsegling med flipoff-hætte.
1 ml solution for injection (40 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml injektionsvæske, opløsning (500 µg/ml darbepoetin alfa) i en fyldt injektionssprøjte af type 1-glas med en 27 gauge kanyle af rustfrit stål.
1 ml solution for injection (500 µg/ml darbepoetin alfa) in a type 1 glass pre-filled syringe with stainless steel 27 gauge needle.
1 ml injektionsvæske, opløsning (500 µg/ml darbepoetin alfa) i en fyldt pen med en sprøjte af type 1-glas og en 27 gauge kanyle af rustfrit stål.
1 ml solution for injection (500 µg/ml darbepoetin alfa) in a pre-filled pen with type 1 glass syringe and stainless steel 27 gauge needle.
1 ml injektionsvæske, opløsning (60 µg/ml darbepoetin alfa) i et hætteglas af type 1-glas med fluoropolymer-belagt elastomerprop og aluminiumsforsegling med flipoff-hætte.
1 ml solution for injection (60 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml injektionsvæske, opløsning i fyldt injektionssprøjte (Type I glas) med fast stål-injektionsnål og stempelprop med PTFE-belægning.
1 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
1 ml injektionsvæske, opløsning indeholder 244 mg (0,25 mmol) gadofosvesettrinatrium svarende til 227 mg gadofosveset
1 ml Ablavar solution contains 244 mg (0.25 mmol) gadofosveset trisodium equivalent to 227 mg of gadofosveset.
1 ml injektionsvæske, opløsning, indeholder 300 MBq florbetaben (18F) på datoen og tidspunktet for kalibrering.
1 mL of solution for injection contains 300 MBq of florbetaben (18F) at the date and time of calibration.
1 ml injektionsvæske, opløsning, indeholder 300 MBq florbetaben (18F) på datoen og tidspunktet for kalibrering.
Each mL of solution for injection contains 300 MBq of florbetaben (18F) at the date and time of calibration.
1 ml injektionsvæske, opløsning, indeholder 40 mg aflibercept*.
1 ml solution for injection contains 40 mg aflibercept*.
1 ml Insulin Human Comb 15 indeholder 100 IE (Internationale Enheder) af det aktive stof human insulin.
One ml of Insulin Human Winthrop Comb 15 contains 100 IU (International Units) of the active substance insulin human.
1 ml Insulin Human Comb 25 indeholder 100 IE (Internationale Enheder) af det aktive stof human insulin.
One ml of Insulin Human Winthrop Comb 25 contains 100 IU (International Units) of the active substance insulin human.
1 ml Insulin Human Comb 30 indeholder 100 IE (Internationale Enheder) af det aktive stof human insulin.
One ml of Insulin Human Winthrop Comb 30 contains 100 IU (International Units) of the active substance insulin human.
1 ml Insulin Human Comb 50 indeholder 100 IE (Internationale Enheder) af det aktive stof human insulin.
One ml of Insulin Human Winthrop Comb 50 contains 100 IU (International Units) of the active substance insulin human.
1 ml Insulin Human Winthrop Basal indeholder 40 IE (Internationale Enheder) af det aktive stof human insulin.
One ml of Insulin Human Winthrop Basal contains 40 IU (International Units) of the active substance insulin human.
1 ml Insulin Human Winthrop Infusat indeholder 100 IE (Internationale Enheder) af det aktive stof human insulin.
One ml of Insulin Human Winthrop Infusat contains 100 IU (International Units) of the active substance insulin human.
1 ml Insuman Basal indeholder 40 IE (Internationale Enheder) af det aktive stof human insulin.
One ml of Insuman Basal contains 40 IU (International Units) of the active substance insulin human.
1 ml Kaletra oral opløsning indeholder 356,3 mg alkohol og 152,7 mg propylenglykol.
Each 1 ml of Kaletra oral solution contains 356.3 mg of alcohol and 152.7 mg of propylene glycol.
1 ml KIOVIG indeholder 100 mg humant protein, hvoraf mindst 98 % er immunglobulin G (IgG).
1 ml of KIOVIG contains 100 mg of human protein of which at least 98% is immunoglobulin G (IgG).
1 ml koncentrat indeholder 0,144 mmol (3,31 mg) natrium.
One ml of concentrate contains 0.144 mmol (3.31 mg) sodium.
1 ml koncentrat indeholder 1 mg clofarabin.
Each ml contains 1 mg of clofarabine.
1 ml koncentrat indeholder 10 mg reslizumab.
Each mL of concentrate contains 10 mg of reslizumab.
1 ml koncentrat indeholder 25 mg bevacizumab*.
Each ml of concentrate contains 25 mg of bevacizumab*.
1 ml koncentrat indeholder 25 mg vinflunin (som ditartrat).
One mL of concentrate contains 25 mg of vinflunine (as ditartrate).
1 ml koncentrat indeholder 3,5 mg dinutuximab.
1 mL of concentrate contains 3.5 mg of dinutuximab.
1 ml koncentrat indeholder 5 mg ipilimumab.
Each ml of concentrate contains 5 mg ipilimumab.
1 ml koncentrat indeholder 50 mg tedizolidphosphat efter rekonstitution.
After reconstitution each mL contains 50 mg tedizolid phosphate.
1 ml koncentrat indeholder, hvad der svarer til 5 mg irinotecanhydrochloridtrihydrat (som irinotecansucrosofatsalt i en pegyleret liposomal formulering) svarende til 4,3 mg irinotecan.
One ml of concentrate contains the equivalent of 5 mg irinotecan hydrochloride trihydrate (as irinotecan sucrosofate salt in a pegylated liposomal formulation) which corresponds to 4.3 mg irinotecan.
1 ml koncentrat til infusionsvæske, opløsning, indeholder 1 mg agalsidase alfa.
1 ml of concentrate for solution for infusion contains 1 mg of agalsidase alfa*.
1 ml koncentrat til infusionsvæske, opløsning, indeholder 4 mg topotecan (som hydrochlorid).
1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
1 ml KRYSTEXXA injiceres i en enkelt 250 ml pose med natriumklorid, 4,5 mg/ml (0,45 %) eller 9 mg/ml (0,9 %) injektionsvæske eller infusionsvæske.
4.5 mg/ml (0.45%) or 9 mg/ml (0.9%) solution for injection or infusion.
1 ml Norvir opløsning (som farmakokinetisk forstærker) indeholder 344,0 mg ethanol og 265,7 mg propylenglycol.
1 ml of Norvir solution (for pharmacokinetic enhancer purposes) contains 344.0 mg of alcohol and 265.7 mg propylene glycol.
1 ml Norvir oral opløsning indeholder 344,0 mg alkohol og 265,7 mg propylenglycol.
Each 1 ml of Norvir oral solution contains 344.0 mg of alcohol and 265.7 mg of propylene glycol.
1 ml og 10 ml hætteglas
Vial of 1 ml or 10 ml
1 ml og 10 ml hætteglas: 4 år.
1 ml and 10 ml glass vials: 4 years.
1 ml ONIVYDE indeholder 0,144 mmol (3,31 mg) natrium.
Each ml of ONIVYDE contains 0.144 mmol (3.31 mg) sodium.
1 ml opløsning (svarende til 10 MIE) i et hætteglas (type I glas), med en prop (halobutylgummi) i et aftageligt segl (aluminium) med en hætte (polypropylen) med 1 injektionssprøjte, 1 kanyle og 1 renseserviet.
1 ml of solution (corresponding to 10 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip- off seal (aluminium) with a bonnet (polypropylene) with 1 injection syringe, 1 injection needle and 1 cleansing swab.
1 ml opløsning (svarende til 10 MIE) i et hætteglas (type I glas), med en prop (halobutylgummi) i et aftageligt segl (aluminium) med en hætte (polypropylen).
1 ml of solution (corresponding to 10 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip- off seal (aluminium) with a bonnet (polypropylene)
1 ml opløsning i en 1 ml injektionssprøjte af type I glas med en fast kanyle af rustfrit stål og et kanylehylster indeholdende tørt naturgummi (et derivat af latex).
1 mL solution in a type I glass 1 mL syringe with a fixed stainless steel needle and a needle cover containing dry natural rubber (a derivative of latex).
1 ml opløsning i type 1-hætteglas med 2 ml lukket med en overtrukken butylgummiprop.
1 mL solution in a type I glass 2 mL vial closed with a coated butyl rubber stopper.
1 ml opløsning indeholder 0,3 mg bimatoprost og 5 mg timolol (svarende til 6,8 mg timololmaleat).
One ml of solution contains 0.3 mg bimatoprost and 5 mg timolol (as 6.8 mg of timolol maleate)
1 ml opløsning indeholder 0,3 mg bimatoprost og 5 mg timolol (svarende til 6,8 mg timololmaleat).
One ml of solution contains 0.3 mg bimatoprost and 5 mg timolol (as 6.8 mg of timolol maleate).
1 ml opløsning indeholder 0,3 mg bimatoprost.
One ml of solution contains 0.3 mg bimatoprost.
1 ml opløsning indeholder 0,9 mg bromfenac (i form af natriumsesquihydrat).
ml of solution contains 0.9 mg bromfenac (as sodium sesquihydrate).
1 ml opløsning indeholder 1 mg olopatadin (som hydrochlorid)
1 mL of solution contains 1 mg olopatadine (as hydrochloride).
1 ml opløsning indeholder 10 mg sildenafil (som citrat) efter rekonstituering.
After reconstitution 1 ml contains 10 mg of sildenafil (as citrate).
1 ml opløsning indeholder 10 mg sildenafil (som citrat) efter rekonstituering.
After reconstitution each ml of the suspension contains 10 mg of sildenafil (as citrate).
1 ml opløsning indeholder 10 mikrogram iloprost (som iloprosttrometamol).
1 ml solution contains 10 microgram iloprost (as iloprost trometamol).
1 ml opløsning indeholder 100 enheder (E) insulin degludec.
Each mL of solution contains 100 units (U) of insulin degludec.
1 ml opløsning indeholder 100 enheder insulin aspart* (svarende til 3,5 mg).
1 ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg).
1 ml opløsning indeholder 100 enheder insulin degludec (svarende til 3,66 mg)
1 mL solution contains 100 units of insulin degludec (equivalent to 3.66 mg)
1 ml opløsning indeholder 100 enheder insulin glargin.
Each ml of the solution contains 100 units of insulin glargine (equivalent to 3.64 mg).
1 ml opløsning indeholder 20 mg methylnaltrexonbromid.
One mL of solution contains 20 mg of methylnaltrexone bromide.
1 ml opløsning indeholder 20 mikrogram iloprost (som iloprosttrometamol).
1 ml solution contains 20 microgram iloprost (as iloprost trometamol).
1 ml opløsning indeholder 200 enheder (E) insulin degludec.
Each mL of solution contains 200 units (U) of insulin degludec.
1 ml opløsning indeholder 200 enheder insulin degludec (svarende til 7,32 mg)
1 mL solution contains 200 units of insulin degludec (equivalent to 7.32 mg)
1 ml opløsning indeholder 30 mikrogram travoprost
1 mL of solution contains 30 micrograms of travoprost
1 ml opløsning indeholder 40 mikrogram travoprost og 5 mg timolol (som timololmaleat).
Each ml of solution contains 40 micrograms travoprost and 5 mg timolol (as timolol maleate).
1 ml opløsning indeholder 925 MBq på kalibreringstids-punktet (01h00 CET, centraleuropæisk tid), svarende til mindst 0,25 μg kobber-
1 mL of solution contains 925 MBq at calibration time (01h00 a.m.
1 ml opløsning indeholder fentanylcitrat svarende til 1000 mikrogram fentanyl.
Each ml of solution contains fentanyl citrate equivalent to 1,000 micrograms fentanyl.
1 ml opløsning indeholder fentanylcitrat svarende til 2000 mikrogram fentanyl.
Each ml of solution contains fentanyl citrate equivalent to 2,000 micrograms fentanyl.
1 ml opløsning indeholder fentanylcitrat svarende til 500 mikrogram fentanyl.
Each ml of solution contains fentanyl citrate equivalent to 500 micrograms fentanyl.
1 ml opløst vaccine indeholder:
Each ml of reconstituted vaccine contains:
1 ml opløst vaccine ved subkutan injektion.
1 ml reconstituted vaccine, via subcutaneous injection.
1 ml oral opløsning indeholder 20 mg abacavir (som sulfat).
Each ml of oral solution contains 20 mg of abacavir (as sulfate)
1 ml oral suspension indeholder 10 mg nevirapin (som hemihydrat)
Each ml of oral suspension contains 10 mg of nevirapine (as hemihydrate)
1 ml oral suspension indeholder 40 mg posaconazol.
Each ml of oral suspension contains 40 mg of posaconazole.
1 ml rekonstitueret dispergering indeholder 8 mikroliter sulphurhexafluorid mikrobobler
1 ml of the reconstituted dispersion contains 8 microlitres sulphur hexafluoride microbubbles.
1 ml rekonstitueret dispergering indeholder 8 mikroliter sulphurhexafluorid mikrobobler
One ml contains 8 µl of sulphur hexafluoride microbubbles
1 ml rekonstitueret opløsning indeholder 90 mg enfuvirtid.
1 ml of reconstituted solutions contains 90 mg enfuvirtide.
1 ml rekonstitueret vaccine indeholder:
Each ml of reconstituted vaccine contains:
1 ml sammenblandet suspension indeholder 40 mg voriconazol (se afsnit 3 "Sådan skal De bruge VFEND").
One ml of the constituted suspension contains 40 mg voriconazole. (See section 3 ‘How to take VFEND’).
1 ml solvens i oral applikator (type I glas) med en stempelprop og en beskyttelseshætte (butylgummi).
1 ml of solvent in an oral applicator (type I glass) with a plunger stopper and a protective tip cap (rubber butyl).
1 ml sprøjte
1 ml injection syringe
1 ml sprøjte (lille sprøjte) med en 13 mm nål
One 1 ml syringe (smaller syringe) with a 13 mm needle
1 ml sprøjte med Luer lock-spids x1
1 ml Luer-lock tip syringe x1
1 ml steril opløsning indeholder 0,1-300 GBq Yttrium (90Y) på referencedatoen og-tidspunktet (svarende til 0,005-15 mikrogram Yttrium [90Y]) (som [90Y] Yttriumchlorid).
1 ml sterile solution contains 0.1-300 GBq Yttrium (90Y) on the reference date and time (corresponding to 0.005-15 micrograms of Yttrium [90Y]) (as Yttrium [90Y] chloride).
1 ml steril opløsning indeholder 0.1-300 GBq (90Y) Yttrium på referencedatoen og –tidspunktet (svarende til 0.005-15 mikrogram [90Y] Yttrium) (som [90Y] Yttriumchlorid).
1 ml sterile solution contains 0.1-300 GBq Yttrium (90Y) on the reference date and time (corresponding to 0.005-15 micrograms of Yttrium [90Y]) (as Yttrium [90Y] chloride).
1 ml steril opløsning indeholder 1,850 GBq yttriumchlorid (90Y) på kalibreringsdatoen, svarende til 92 ng yttrium.
1 ml of sterile solution contains 1.850 GBq Yttrium (90Y) chloride, at the date of calibration, corresponding to 92 ng of Yttrium.
1 ml suspension i et hætteglas (type I glas) til 2 doser med en prop (butylgummi) i følgende pakningsstørrelser:
1 ml of suspension in a vial (type I glass) for 2 doses with a stopper (rubber butyl) in the following pack sizes:
1 ml suspension i fyldt injektionssprøjte (type I glas) med en prop (butylgummi).
1 ml of suspension in a prefilled syringe (type I glass) with a plunger stopper (rubber butyl).
1 ml suspension i fyldt injektionssprøjte (type I glas) med sprøjtestempel (butylgummi).
1 ml of suspension in a prefilled syringe (type I glass) with a plunger stopper (rubber butyl).
1 ml suspension i hætteglas (glas) med prop (gråt butylgummi) og aluminiumforsegling med vip-af- hætte i plastic.
1 ml of suspension in vial (glass) with stopper (gray butyl rubber) and aluminum seals with plastic flip caps.
1 ml suspension i hætteglas (glas) med prop (gråt butylgummi) og aluminiumforsegling med vip-af- hætte.
1 ml of suspension in vial (glass) with stopper (gray butyl rubber) and aluminum seals with plastic flip caps.
1 ml suspension i hætteglas (type I glas) med en prop (butylgummi).
1 ml of suspension in a vial (type I glass) with a plunger stopper (rubber butyl).
1 ml suspension i hætteglas (type I-glas) til 2 doser og med prop (butylgummi).
1 ml suspension in a vial (type I glass) with a stopper (butyl rubber) for 2 doses.
1 ml suspension indeholder 1 mg nepafenac.
One ml of suspension contains 1 mg of nepafenac.
1 ml suspension indeholder 10 mg brinzolamid og 2 mg brimonidin-tartrat
1 ml of suspension contains 10 mg brinzolamide and 2 mg brimonidine tartrate
1 ml suspension indeholder 10 mg brinzolamid og 2 mg brimonidin-tartrat svarende til 1,3 mg brimonidin.
One ml of suspension contains 10 mg of brinzolamide and 2 mg of brimonidine tartrate equivalent to 1.3 mg brimonidine.
1 ml suspension indeholder 10 mg brinzolamid og 5 mg timolol (som timololmaleat)
1 ml of suspension contains 10 mg brinzolamide and 5 mg timolol (as timolol maleate)
1 ml suspension indeholder 10 mg brinzolamid og 5 mg timolol (som timololmaleat).
One ml of suspension contains 10 mg brinzolamide and 5 mg timolol (as timolol maleate).
1 ml suspension indeholder 10 mg/ml brinzolamid
Each ml of suspension contains 10 mg of brinzolamide
1 ml suspension indeholder 100 enheder opløselig insulin aspart/protaminkrystalliseret insulin aspart i forholdet 30/70 (svarende til 3,5 mg).
1 ml suspension contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70 (equivalent to 3.5 mg).
1 ml suspension indeholder 100 enheder opløselig insulin aspart/protaminkrystalliseret insulin aspart i forholdet 50/50 (svarende til 3,5 mg).
1 ml suspension contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 50/50 (equivalent to 3.5 mg).
1 ml suspension indeholder 100 enheder opløselig insulin aspart/protaminkrystalliseret insulin aspart i forholdet 70/30 (svarende til 3,5 mg).
1 ml suspension contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 70/30 (equivalent to 3.5 mg).
1 ml suspension indeholder 100 IE (3,5 mg) humant insulin (rDNA)
1 ml suspension contains 100 IU (3.5 mg) of insulin human, rDNA
1 ml suspension indeholder 20 mg mercaptopurin (som monohydrat).
One ml of suspension contains 20 mg mercaptopurine (as monohydrate).
1 ml suspension indeholder 20 mg mercaptopurin- monohydrat.
One ml of suspension contains 20 mg of mercaptopurine monohydrate.
1 ml suspension indeholder 3 mg nepafenac.
One ml of suspension contains 3 mg of nepafenac.
1 ml suspension indeholder 40 IE (1,4 mg) humant insulin (rDNA)
1 ml suspension contains 40 IU (1.4 mg) of insulin human, rDNA
1 ml suspension indeholder 40 IE (Internationale Enheder) af det aktive stof human insulin.
One ml of Insuman Comb 15 contains 40 IU (International Units) of the active substance insulin human.
1 ml type 1 glas injektionssprøjte med kanyle af rustfri stål indeholder 0,5 ml injektionsvæske.
One mL type 1 glass syringe, with a stainless steel needle, containing 0.5 mL solution.
1 ml type 1 glas injektionssprøjte med kanyle af rustfri stål indeholder 0,5 ml opløsning.
One mL type 1 glass syringe, with a stainless steel needle, containing 0.5 mL solution.
1 ml vandig opløsning indeholder 10 mikrogram iloprost (som iloprosttrometamol).
1 ml solution contains 10 microgram iloprost (as iloprost trometamol).
1 ml vandig opløsning indeholder 20 mikrogram iloprost (som iloprosttrometamol).
1 ml solution contains 20 microgram iloprost (as iloprost trometamol).
1 ml øjendråber indeholder 1mg olopatadin (som hydrochlorid)
Each mL of solution contains 1mg of olopatadine (as hydrochloride).
1 ml-ampul gul-rød ring
1 ml ampoule yellow-red ring
1 ml-ampul hvid-gul ring
1 ml ampoule white-yellow ring
1 ml. sprøjte) og injektionsnål (f.eks.
1 ml syringe) and injection needle (e.g.
1 ml/fyldt injektionssprøjte
1 mL/pre-filled syringe
1 ml/hætteglas
1 mL/vial
1 ml: Dexmedetomidin hydrochlorid 0,1 mg
1 ml: Dexmedetomidine hydrochloride 0.1 mg
1 multidosis gætteglas (Polyethylen- terepthalat ) (PET)
1 multidose bottle (polythylene terephthalate) (PET)
1 multidosis hætteglas (glas)
1 multidose bottle (glass)
1 Målt ved første operation, hvis der var mere end en operation.
1 Measured at first session, if there was more than one surgery session.
1 måned efter booster
1 month after booster
1 måned til <12 år (N = 18)
1 month to <12 years (N = 18)
1 måneds dosering var stort set reversible inden for 1 måned efter seponering med undtagelse af delvis bedring for nogle af forandringerne i cornea.
The findings present following 1 month of dosing were largely reversible within 1 month of cessation of dosing with the exception of partial recovery for some of the corneal changes.
1 nasal applikator til engangsbrug (0,2 ml) 10 nasale applikatorer til engangsbrug (0,2 ml)
1 single-use nasal applicator (0.2 ml) 10 single-use nasal applicators (0.2 ml each)
1 NCI CTC grad 2 obstipation er defineret som krævende laksans, grad 3 kræver manuel fjernelse eller lavement, grad 4 som obstruktion eller toksisk megacolon.
1 NCI CTC Grade 2 constipation is defined as requiring laxatives, Grade 3 as an obstipation requiring manual evacuation or enema, Grade 4 as an obstruction or toxic megacolon.
1 NCI CTCAE v 4.0 = National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
1 NCI CTCAE v 4.0 = National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
1 NCI-CTC grad 2 obstipation er defineret som krævende laksans, grad 3 kræver manuel fjernelse eller lavement, grad 4 som obstruktion eller toksisk megacolon.
1 NCI CTC Grade 2 constipation is defined as requiring laxatives, Grade 3 as an obstipation requiring manual evacuation or enema, Grade 4 as an obstruction or toxic megacolon.
1 nål til tilberedning
1 needle for preparation
1 Når der et angivet doser, er det de doser, der er anvendt i kliniske lægemiddelinteraktionsstudier.
1 When doses are provided, they are the doses used in clinical drug-drug interaction studies.
1 Observeret under brug ved lumbal interkorporal fusion
1 Observed during use in lumbar interbody fusion
1 of 1
tablets
1 og 2).
1 and 2)
1 Omfatter abdominalsmerte (N=1), dyspepsis (N=1).
1 Includes abdominal pain (N=1) and dyspepsia (N=1).
1 Omfatter abdominalsmerte (N=1), synkebesvær (N=1) og epigastriske gener (N=1).
1 Includes abdominal pain (N=1), dysphagia (N=1) and epigastric discomfort (N=1).
1 Omfatter paronykie, negleinfektion, neglelejeinfektion
1 Includes Paronychia, Nail infection, Nail bed infection
1 Omfatter paronykie, negleinfektion, neglelejeinfektion.
1 Includes Paronychia, Nail infection, Nail bed infection
1 Ons.
1 Wed.
1 Oprymea 0,26 mg depottablet.
One Oprymea 0.26 mg prolonged-release tablet.
1 Organområde af interesse 2 Sacrumområde af interesse
2 Sacrum region of interest
1 overførselsanordning med filter 20/20 [Mix2Vial]
1 filter transfer device 20/20 [Mix2Vial]
1 overførselsanordning, der anvendes i forbindelse med fremstilling af infusionsvæsken
1 transfer device for reconstitution
1 overførselsenhed (Mix2Vial)
1 Transfer Device (Mix2Vial)
1 Ovis
Ovis
1 Ovis
ZULVAC 1
1 p < 0,001.
1 p < 0.001.
1 p-værdi for PFS/OS baseret på stratificeret log-rank test
1 p-value for PFS/OS based on stratified log-rank test
1 p-værdi for sammeligning af standard-dosis versus lav-dosis.
1 p value for Standard Dose versus Low Dose comparison.
1 p-værdien for PFS/OS baseret på stratificeret log-rank test; p-værdi for objektiv responsrate baseret på logistisk regression
1 p-value for PFS/OS based on stratified log-rank test; p-value for Objective Response Rate based on logistic regression
1 pakke med 3 kanyler
1 pack with 3 pen needles
1 pakning indeholder:
1 pack containing:
1 patient trak sit samtykke tilbage
1 patient withdrew consent
1 Patienter med >én dosis testmedicin med vurderbare leverbiopsier ved studiestart og Knodells histologiske aktivitetsindeks (HAI)-score >3 ved studiestart.
1 Patients with ≥ one dose of study drug with evaluable baseline liver biopsies and baseline Knodell Histological Activity Index (HAI) score > 3.